A Randomized Investigation of High-Dose Versus Standard Dose Cytosine Arabinoside with Daunorubicin in Patients with Acute Non-Lymphocytic Leukemia
Publication Information Expand/Collapse
PMid: PMID30315233 | PMC number: PMC6367002
PMid: PMID29370458 | PMC number: PMC5963502
PMid: PMID27986655 | PMC number: PMC5370550
PMid: PMID28222251; PMC5705230
PMid: PMID27055872 | PMC number: PMC4980556
PMid: PMID25113226 | PMC number: PMC4318722
PMid: PMID24383844 | PMC number: PMC4117470
PMid: PMID23760400 | PMC number: PMC4457325
Association between BMI at treatment initiation and cancer survival across multiple SWOG trials
PMid: PMID24104597 | PMC number: PMC3833872
PMid: PMID23325837 | PMC number: PMC3612855
PMid: PMID21928314 | PMC number: PMC3490403
PMid: PMID22315487 | PMC number: PMCID3436242
Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype [PMID21330329; PMC3069244]
Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation [PMID21680797;PMC3156042]
Cytarabine dose for acute myeloid leukemia. (Letter to the Editor) [PMID21631340]
Prediction of early death following induction therapy for newly diagnosed acute leukemia with pretreatment risk scores: a novel paradigm for treatment assignment
PMid: PMID21969499 | PMC number: PMC3221524
The effect of complete remission (CR) and CR with incomplete platelet recovery (CRp) on outcome in acute myeloid leukemia: a combined eastern cooperative oncology group (ECOG), Southwest Oncology Group (SWOG), and M.D. Anderson Cancer Center study
PMid: PMID20562328 | PMC number: PMC3709629
Outcome of adolescents and young adults (AYAs) with non-M3 acute myeloid leukemia (AML) treated on Children's Oncology Group (COG) trials compared to Cancer and Leukemia Group B (CALGB) and Southwest Oncology Group (SWOG) trials
Influence of residual normal metaphases in patients with monosomal karyotype
Very late antigen-4 (VLA-4) function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia [PMC2630271; PMID18927435]
Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328
Minority report: how best to analyze clinical trial data to address disparities
The Southwest Oncology Group: progress in cancer research [PMID18929152]
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
Methylation profiling in acute myeloid leukemia
Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia
Acute myelogenous leukemia and aging. Clinical interactions.
Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia.
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-Glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study
CPG island methylator phenotype in acute myelogenous leukemia
Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells
P73 mutations and expression in adult de novo acute myelogenous leukemia
Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein.
Cell cycle arrest and therapeutic sensitivity in de novo AML.
Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia (AML).
Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia.
Long-term survival after chemotherapy for acute myeloid leukemia: The experience of the Southwest Oncology Group.
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study.
Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia.
Estrogen receptor methylation is a favorable prognostic factor in AML.
Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukemia.
Methods to detect p-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations.
Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells.
Spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia.
Characterization and rapid diagnostic utility of a novel antibody detecting the CBFB/SMMHC fusion protein of inversion(16)/t(16;16) associated acute myeloid leukemia.
The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias.
Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia.
Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux- cases
Genetic heterogeneity of acute myeloid leukemia (AML) with FAB-AML M3 morphology
Heterogeneity in CBFB/MYH11 fusion messages encoded by inv(16) and t(16;16) in acute myelogenous leukemia (AML)
Amplification of the E2F-1 transcription factor gene in the HEL erythroleukemia cell line
Heterogeneity in CBF'/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia
Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia.
Trisomy 11: an association with stem/progenitor cell immunophenotype.
Multidrug resistance (MDR1) expression and function in acute myeloid leukemia (AML) in the elderly: MDR1 and secondary AML status are independent predictors of complete remission (CR).
Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group.
Consistent loss of the D5S89 locus mapping telomeric to the interleukin gene cluster and centromeric to EGR-1 in patients with 5q- chromosome
CD56: A determinant of extramedullary and central nervous system (CNS) involvement in acute myeloid leukemia (AML). Modern Pathology 7(1):120A (#695)
Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience.
HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3
Trisomy 8: A primary cytogenetic anomaly in leukemia?
Comparative genomic hybridization (CGH) and cytogenetics provide complementary information to identify genetic abnormalities in AML.
Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia (AML).
Correlation of functional efflux and multidrug resistance (MDR1) expression in acute myeloid leukemia (AML) in the elderly: MDR1 and secondary AML status are independent predictors of complete remission (CR).
Deletion of gene for multidrug resistance in acute myeloid leukemia with inversion in chromosome 16: prognostic implications
Acute promyelocytic leukemia associated wit t(11;17) is a discrete syndrome that fails to respond to retinoic acid.
Reply to comments by Fenaux and Warrell.
An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the t(8;21) (q22;q22).
HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities.
Identification and characterization of a previously unrecognized form of acute leukemia co-expressing myeloid and natural killer (NK) cell-associated antigens (CD56).
Clinical significance and functional analysis of the expression of the multidrug resistance gene (MDR1) in acute myeloid leukemia (AML).
Functional assessment of the multidrug (MDR1) resistance efflux pump in acute myeloid leukemia (AML): Identification of CD34-, CD33+, MRK16+ (MDR1+) cases lacking functional dye efflux.
Clinical and molecular characterization of the acute promyelocytic leukemia (APL) associated with the t(11;17) and PLZF-RAR fusion.
Development of a highly sensitive ploymerase chain reaction detect allele loss in the 5q-chromosome.
N-ras mutations in acute myelogenous leukemia: A review of the current literature and an update of the Southwest Oncology Group experience.
False positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts.
Activation of EVI-1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26.
A randomized investigation of high-dose (HDAC) versus standard dose (SDAC) cytosine arabinoside with daunorubicin (DNR) in patients with acute myelogenous leukemia.
Biologic parameters that predict treatment response in de novo acute myeloid leukemia (AML): CD34, but not multidrug resistance (MDR) gene expression, is associated with a decreased complete remission (CR) rate and CD34+ patients more frequently achieve CR with high dose cytosine arabinoside.
Biochemical modulation of anthracycline resistance (MDR) in acute leukemia with cyclosporin-A (CSA).
Chromosomal rearrangements 3' of the EV1 myeloid transforming gene activate expression in human acute myelogenous leukemia.
Interferon regulatory factor-1 (IRF-1): A candidate tumor suppressor gene on chromosome 5q31-1 deleted in leukemia and myelodysplasia (MDS) with del (5q) or translocation of 5q31.
The human cell cycle gene CDC25C maps to chromosome 5q31.1 within 100 KB of interferon regulatory factor-1 (IRF-1) in the critical region deleted in myelodysplasia (MDS) and leukemia with 5q abnormalities.
Evaluation of the proliferative fraction of cytogenetically normal and aberrant hemopoietic subpopulations in acute myeloid leukemia (AML and myelodysplasia (MDS).
Variable frequency of cytogenetically aberrant cells in the stem cell compartment and hemopoietic lineages in acute myeloid leukemia (AML) and myelodysplasia (MDS).
Precise localization of the long arm breakpoint of the inv(16) of ANNL M4Eo and progress towards cloning this breakpoint.
Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages.
Multiparameter analysis of the expression of the multidrug resistance genes MDR1 and MDR2 (MDR3) in de novo AML by polymerase chain reaction (PCR) and multicolor flow cytometry: Identification of a biological subset of CD34+, MDR1 + AML cases.
Multidrug resistance in CD34+ acute leukemia correlates with non-lymphoid lineage.
Multiparameter analysis of acute mixed lineage leukemia: Correlation of aB/Myeloid immunophenotype and immunoglobulin and T-cell gene rearrangements with the presence of the Philadelphia chromosome translocation in acute leukemias with
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.
N-ras mutations in adult de novo acute myelogenous leukemia: Prevalence and clinical significance.
Cloning and characterization of the (15;17) translocation break point region in acute promyelocytic leukemia.
The molecular biology of acute myeloid leukemia. Proto-oncogene expression and function in normal and neoplastic myeloid cells.
Analysis of MDR1 gene expression in clinical tumor samples by polymerase chain reaction (PCR).
Expression of the EVI-1 gene encoding a DNA-binding protein in AMLs with karyotypic abnormalities of chromosome 3q.
Multiparameter analysis of acute mixed lineage leukemia: Correlation of B/Myeloid immunophenotype and immunoglobulin and T-cell gene rearrangements with the presence of the Philadelphia chromosome translocation in acute leukemias with myeloid morphology.
Biological parameters associated with therapeuticnon-responsiveness in a cute myeloid leukemia (AML).